To test this hypothesis, we evaluated tumor and serum miR expression immediately after short-term treatment of pancreatic tumor xenografts with either the FGFR or ALK inhibitor in a COLO357PL [33,34,35] model expressing both FGFR and ALK receptors [20,22]. The gene discussed is ALK; the disease is pancreatic neoplasm.